| 3668 |
2379: Disruption, regulatory function of dopamine signaling components. |
2380: Increase, dopamine transporter gene |
Oct 20, 2025 |
Oct 20, 2025 |
1 AOP
|
| 3669 |
2379: Disruption, regulatory function of dopamine signaling components. |
2381: Increase, dopamine receptor gene |
Oct 20, 2025 |
Oct 20, 2025 |
1 AOP
|
| 3670 |
2380: Increase, dopamine transporter gene |
746: Increase, Dopaminergic activity |
Oct 20, 2025 |
Oct 20, 2025 |
1 AOP
|
| 3671 |
2381: Increase, dopamine receptor gene |
746: Increase, Dopaminergic activity |
Oct 20, 2025 |
Oct 20, 2025 |
1 AOP
|
| 3672 |
746: Increase, Dopaminergic activity |
602: Increased, Ataxia, paralysis, or hyperactivity |
Oct 20, 2025 |
Oct 20, 2025 |
1 AOP
|
| 3673 |
602: Increased, Ataxia, paralysis, or hyperactivity |
1005: Reduced, Swimming performance |
Oct 20, 2025 |
Oct 20, 2025 |
1 AOP
|
| 3674 |
1005: Reduced, Swimming performance |
2382: Increase, nerve spasm |
Oct 20, 2025 |
Oct 20, 2025 |
1 AOP
|
| 3675 |
227: Activation, PPARα |
1312: Increase, Fatty acid β-oxidation |
Oct 30, 2025 |
Oct 30, 2025 |
2 AOPs
|
| 3676 |
1312: Increase, Fatty acid β-oxidation |
1446: Decrease, Coupling of OXPHOS |
Oct 30, 2025 |
Oct 30, 2025 |
2 AOPs
|
| 3677 |
1771: Decrease, ATP pool |
2384: Decrease, Vascular integrity |
Oct 30, 2025 |
Oct 30, 2025 |
1 AOP
|
| 3678 |
2384: Decrease, Vascular integrity |
2383: Increase, Hemopericardium |
Oct 30, 2025 |
Oct 30, 2025 |
2 AOPs
|
| 3679 |
2383: Increase, Hemopericardium |
947: Increase, Early Life Stage Mortality |
Oct 30, 2025 |
Oct 30, 2025 |
3 AOPs
|
| 3680 |
1115: Increase, ROS |
2384: Decrease, Vascular integrity |
Oct 30, 2025 |
Oct 30, 2025 |
1 AOP
|
| 3681 |
227: Activation, PPARα |
948: reduced production, VEGF |
Oct 30, 2025 |
Oct 30, 2025 |
1 AOP
|
| 3682 |
948: reduced production, VEGF |
28: Reduction, Angiogenesis |
Oct 30, 2025 |
Oct 30, 2025 |
1 AOP
|
| 3683 |
28: Reduction, Angiogenesis |
2383: Increase, Hemopericardium |
Oct 30, 2025 |
Oct 30, 2025 |
1 AOP
|
| 3684 |
2385: Suppression of Keap1 cysteine oxidation |
1417: NFE2/Nrf2 repression |
Nov 4, 2025 |
Nov 4, 2025 |
1 AOP
|
| 3685 |
1417: NFE2/Nrf2 repression |
2386: Lipid-peroxidation overload |
Nov 4, 2025 |
Nov 4, 2025 |
None
|
| 3686 |
2386: Lipid-peroxidation overload |
1994: Ferroptosis |
Nov 4, 2025 |
Nov 4, 2025 |
None
|
| 3687 |
1994: Ferroptosis |
902: Inflammation, Liver |
Nov 4, 2025 |
Nov 4, 2025 |
1 AOP
|
| 3688 |
2387: Nuclear receptor binding / steroidogenic enzyme interference |
2389: Altered steroidogenesis |
Nov 7, 2025 |
Nov 7, 2025 |
1 AOP
|
| 3689 |
2388: photoproducts generate ROS |
1392: Increase, Oxidative Stress |
Nov 7, 2025 |
Nov 7, 2025 |
1 AOP
|
| 3690 |
1392: Increase, Oxidative Stress |
2363: Mito ROS dysfunction |
Nov 7, 2025 |
Nov 7, 2025 |
1 AOP
|
| 3691 |
2363: Mito ROS dysfunction |
1262: Apoptosis |
Nov 7, 2025 |
Nov 7, 2025 |
1 AOP
|
| 3692 |
2389: Altered steroidogenesis |
2390: reproductive hormonal Imbalance |
Nov 7, 2025 |
Nov 7, 2025 |
1 AOP
|